Optimizing Prophylaxis Strategies of Hemophilia A with or without Inhibitors: For Whom, When, and How Long?

All other health care professionals completing this course will be issued a statement of participation.

Target Audience
The educational design of this activity addresses the needs of hematologists, pediatric hematologists, hematologist-oncologists, pediatricians, pharmacists, hemophilia pharmacists, hemophilia nurses, nurse practitioners, physician assistants, and other clinicians involved in the management of patients with hemophilia.

Statement of Need/Program Overview
Hemophilia A (factor VIII [factor 8] deficiency) is an X-linked inherited coagulation factor deficiency. The management of hemophilia A has improved significantly in recent years with the availability of factor replacement agents, such as with extended half-life replacement agents and non-factor replacement therapy. Unfortunately, the optimal management remains complex and poses significant challenges for clinicians who care for patients with hemophilia. This is highlighted in outcomes results from recent educational activities.

Learning Objectives
After completing this activity, the participant should be better able to:

Identify the numerous clinical factors when determining a therapeutic plan for your patient with hemophilia A
Evaluate the mechanisms, safety, and efficacy of currently available products for bleeding prophylaxis in patients with severe hemophilia A
Summarize the best practices when managing patients with hemophilia A with inhibitors